• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Publication date: Available online 1 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L Bhatt, Vera A Bittner, Andrzej J Budaj, Rafael Diaz, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Virginie Loizeau, Renato D Lopes, Angèle Moryusef, Jan Murin, Robert Pordy, Arsen D Ristic, Matthew T Roe, José TuñónSummaryBackgroundAfter acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with ezetimibe or statins reduces...
Source: The Lancet Diabetes and Endocrinology - July 2, 2019 Category: Endocrinology Source Type: research

Ezetimibe provides particular benefit in patients with diabetes and recent acute coronary syndrome
(Brigham and Women's Hospital) According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Acute coronary syndrome, which includes heart attack and unstable angina, a condition that can lead to a heart attack, are among the leading causes of death and disability worldwide. In addition to lifestyle changes, medications that lower blood cholesterol are helpful in preventing future cardiac and vascular events, including heart attack and stroke.
Source: EurekAlert! - Medicine and Health - August 30, 2015 Category: Global & Universal Source Type: news

Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association. For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news